%0 Journal Article
%T DEVELOPMENT OF ONCE A DAY TRIPLE COMBINATION FORMULATION FOR NIDDM
%A Kumaresan Chandrasekaran
%J Journal of Global Pharma Technology
%D 2010
%I 
%R 10.1234/jgpt.v2i7.232
%X At present there are five classes of oral pharmacological agents available to treat type 2 diabetes as in the classification of Sulphonyl urea, Meglitinide, Biguanide, Thiazolidinedione and ¦Á-Glucose inhibitors. They are available in the form of tablets of the individual drugs, either as immediate release (IR) formulations or in some cases, controlled release formulations. They are administered individually or in combination. The combination therapy is used to provide an optimal level of glycerin control over non-insulin dependent diabetes mellitus (NIDDM) patient. The ease of using combination therapy for multiple medications as opposed to separate administrations of the individual medications has been recognized in the practice of medicine. Such therapy provides therapeutic advantage for the patient and the clinician. The object of the present project work is to develop fixed dose triple combination of antidiabetic drugs wherein Pioglitazone and Glimepride are as immediate release form and Metformin is as extended release (ER) form.
%K Metformin hydrochloride
%K Pioglitazone hydrochloride
%K Glimepiride
%K Extended release
%K Immediate release
%K diabetes.
%U http://jgpt.co.in/jgpt/index.php/jgptjournal/article/view/232